182 related articles for article (PubMed ID: 8329574)
1. Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Puri RN; Colman RW
Blood Coagul Fibrinolysis; 1993 Jun; 4(3):465-78. PubMed ID: 8329574
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of a kininogen-based selective inhibitor of thrombin-induced platelet aggregation.
Matsueda R; Umeyama H; Puri RN; Bradford HN; Colman RW
Pept Res; 1994; 7(1):32-5. PubMed ID: 8019060
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of thrombin- and plasmin-induced platelet aggregation by a synthetic peptide disulfide.
Puri RN; Hu CJ; Bradford HN; Matsueda R; Umeyama H; Colman RW
Trans Assoc Am Physicians; 1989; 102():13-9. PubMed ID: 2561638
[TBL] [Abstract][Full Text] [Related]
4. Modulation of thrombin-induced platelet aggregation by inhibition of calpain by a synthetic peptide derived from the thiol-protease inhibitory sequence of kininogens and S-(3-nitro-2-pyridinesulfenyl)-cysteine.
Puri RN; Matsueda R; Umeyama H; Bradford HN; Colman RW
Eur J Biochem; 1993 May; 214(1):233-41. PubMed ID: 8389701
[TBL] [Abstract][Full Text] [Related]
5. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction.
Parise P; Hauert J; Iorio A; Callegari P; Agnelli G
J Lab Clin Med; 1995 Feb; 125(2):212-21. PubMed ID: 7531212
[TBL] [Abstract][Full Text] [Related]
6. Aggregation of washed platelets by plasminogen and plasminogen activators is mediated by plasmin and is inhibited by a synthetic peptide disulfide.
Puri RN; Hu CJ; Matsueda R; Umeyama H; Colman RW
Thromb Res; 1992 Mar; 65(4-5):533-47. PubMed ID: 1535463
[TBL] [Abstract][Full Text] [Related]
7. [Effect of thrombolytic agents on platelets and blood coagulation system].
Suehiro A
Rinsho Byori; 1997 Oct; 45(10):951-6. PubMed ID: 9369072
[TBL] [Abstract][Full Text] [Related]
8. Plasmin-induced platelet aggregation is accompanied by cleavage of aggregin and indirectly mediated by calpain.
Puri RN; Zhou FX; Colman RF; Colman RW
Am J Physiol; 1990 Dec; 259(6 Pt 1):C862-8. PubMed ID: 2148055
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN.
Kinlough-Rathbone RL; Perry DW; Rand ML; Packham MA
Thromb Haemost; 1997 Apr; 77(4):741-7. PubMed ID: 9134653
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
11. Characterization of plasmin-induced platelet aggregation.
Watabe A; Ohta M; Matsuyama N; Mizuno K; el Borai N; Tanimoto T; Kawanishi T; Hayakawa T
Res Commun Mol Pathol Pharmacol; 1997 Jun; 96(3):341-52. PubMed ID: 9261893
[TBL] [Abstract][Full Text] [Related]
12. Time course of platelet aggregation during thrombolytic treatment of massive pulmonary embolism.
Mühl D; Füredi R; Gecse K; Ghosh S; Falusi B; Bogár L; Roth E; Lantos J
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):661-7. PubMed ID: 17890954
[TBL] [Abstract][Full Text] [Related]
13. [Peptides as inhibitors of thrombin coagulation activity and of thrombocyte aggregation].
Pastorova VE; Liapina LA; Cherkasova KA; Ashmarin IP
Usp Fiziol Nauk; 1999; 30(2):80-91. PubMed ID: 10420478
[TBL] [Abstract][Full Text] [Related]
14. Functional properties of a recombinant chimeric plasminogen activator with platelet-targeted fibrinolytic and anticoagulant potential.
Zhang L; Wang J; Yu M; Ru B
Mol Genet Metab; 2004 Aug; 82(4):304-11. PubMed ID: 15308128
[TBL] [Abstract][Full Text] [Related]
15. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy.
Kuliopulos A; Covic L; Seeley SK; Sheridan PJ; Helin J; Costello CE
Biochemistry; 1999 Apr; 38(14):4572-85. PubMed ID: 10194379
[TBL] [Abstract][Full Text] [Related]
16. Thrombin-induced platelet aggregation involves an indirect proteolytic cleavage of aggregin by calpain.
Puri RN; Zhou FX; Bradford H; Hu CJ; Colman RF; Colman RW
Arch Biochem Biophys; 1989 Jun; 271(2):346-58. PubMed ID: 2543293
[TBL] [Abstract][Full Text] [Related]
17. Cytoskeletal changes in platelets induced by thrombin and phorbol myristate acetate (PMA).
Chen R; Liang N
Cell Biol Int; 1998; 22(6):429-35. PubMed ID: 10328851
[TBL] [Abstract][Full Text] [Related]
18. Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans.
Murphey LJ; Malave HA; Petro J; Biaggioni I; Byrne DW; Vaughan DE; Luther JM; Pretorius M; Brown NJ
J Pharmacol Exp Ther; 2006 Sep; 318(3):1287-92. PubMed ID: 16772538
[TBL] [Abstract][Full Text] [Related]
19. SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis.
Feigen LP; Nicholson NS; King LW; Campion JG; Tjoeng FS; Panzer-Knodle SG
J Pharmacol Exp Ther; 1993 Dec; 267(3):1191-7. PubMed ID: 8263779
[TBL] [Abstract][Full Text] [Related]
20. Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation.
Martínez C; Rivera J; Loyau S; Corral J; González-Conejero R; Lozano ML; Vicente V; Anglés-Cano E
Thromb Haemost; 2001 Apr; 85(4):686-93. PubMed ID: 11341506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
